Eli Lilly Gets FDA OK for Taltz for Non-Radiographic Axial Spondyloarthritis
01 June 2020 - 9:35PM
Dow Jones News
By Colin Kellaher
Eli Lilly & Co. Monday said the U.S. Food and Drug
Administration approved the expanded use of Taltz for the treatment
of active non-radiographic axial spondyloarthritis in patients with
objective signs of inflammation.
The Indianapolis drug maker said Taltz is now approved to treat
patients across the full axial spondyloarthritis spectrum,
including ankylosing spondylitis, also known as radiographic axial
spondyloarthritis.
Axial spondyloarthritis is a disease predominantly affecting the
sacroiliac joints and the spine, resulting in chronic inflammatory
back pain and fatigue.
Eli Lilly said the FDA approval is the fifth for Taltz, which
the agency has also cleared for indications in moderate to severe
plaque psoriasis and active psoriatic arthritis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 01, 2020 07:20 ET (11:20 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.